

Appendix 4C and Activities Report: Prudent Cost Management Amid Softer Market Conditions

ASX Announcement

30 January 2026


Holista Colltech Limited (ASX: HCT, “Holista” or “the Company”) is pleased to provide the following update on its operational and financial performance for the quarter ended 31 December 2025.

Key Highlights

- **Positive Operating Cash Flow Achieved:** Net operating cash inflow of \$238K — a continued turnaround from the \$78K outflow in the prior quarter, reflecting effective cost management.
 - **Robust Liquidity Position:** Cash on hand of \$2.2 million, bolstered by \$1.3 million in undrawn credit facilities, providing a total liquidity buffer of approximately \$3.4 million to support ongoing operations.
 - **Continued Cost Discipline:** Operating costs reduced by 26.8% quarter-on-quarter (QoQ) to \$1.46 million, even after absorbing \$109K in one-off legal expenses.
 - **Customer Receipts and Debt Recovery:** Total receipts of \$1.70 million, supported by successful recovery of \$212K from aged receivables and an \$86K tax refund.
 - **Successful Capital Raising:** Gross proceeds of \$2.3 million raised through share placements, further strengthening the balance sheet.
-

Financial Overview Holista remain focused on operational efficiency and cash conservation in a softer market environment.

- **Cash Flow & Cost Management** — The reversal to positive operating cash flow (\$238K inflow) was driven by a 26.8% QoQ reduction in operating costs to \$1.46 million. This disciplined approach enabled the Company to absorb one-off legal costs without impacting overall cash positivity.
- **Receipts & Revenue Support** — Customer receipts reached \$1.70 million, down 11.4% QoQ due to lower sales volumes, but mitigated by proactive debt recovery efforts.
- **Liquidity & Capital** — Cash reserves stood at \$2.2 million at quarter-end, supported by available credit lines. In line with ASX Listing Rule 4.7C, payments totaling \$42K were made to related parties and their associates during the quarter.



**All sales figures are subject to audit.*

Divisional Performance

Divisional Performance Group sales totaled \$1.15 million for the quarter. The 33.6% QoQ decline was due primarily to a one-off accounting adjustment. Excluding this, underlying sales declined by approximately 11.8%, consistent with broader market softness.


- **Dietary Supplements** (core revenue driver): \$1.11 million in revenue. Reported figure down 26.7% QoQ due to the accounting adjustment; underlying performance remained resilient with only a 1.8% QoQ decline and a 3.0% increase year-on-year (YoY).

For personal use only

- **Food Ingredients:** \$1K in revenue — reflecting temporary demand softness from a key customer; management is closely monitoring this.
- **Ovine Collagen:** \$25K in revenue (-25% QoQ) — variance mainly due to order timing, with no loss of key business.

Pursuant to our binding agreement with Regenerex Pharma Inc made on 26th August 2025, the Company received its first order for U\$51,700 on 24th December 2025. However, shipment can only be made after approvals for special import are obtained in the US. This shipment is for the purposes of clinical trial and regulatory approval as a medical devise with the FDA.

- **Infection Control / Agriculture:** Following the commencement of the agriculture business, revenue of \$9K was recognised for the financial year. During the reporting period, customer orders amounting to \$10K were received; however, no revenue was recognised as at quarter end as the orders had not yet been fulfilled.



**All sales figures are subject to audit.*

Corporate & Strategic Updates

- **Investing Activities:** Net cash outflow of \$138K, mainly attributable to a fixed deposit placement linked to our banking facilities and minor office equipment replacement.
- **Financing Activities:** Net outflow of \$315K from scheduled debt repayments.
- **Capital Management:** The \$2.3 million gross raise via placements has enhanced financial flexibility.

Legal Update – Prolimmune Matters Since the previous update (31 October 2025):

- **Prolimmune Action (CIV1440 of 2025):** The Court identified procedural deficiencies in Prolimmune's initial filing and issued remedial orders deeming the action to have been commenced by writ of summons. Prolimmune was required to file additional court documents to pursue recovery of a US judgment amount.

Following these orders, Prolimmune filed an application for summary judgment, which Holista is actively contesting. After a postponement on 23 October 2025, the application was heard on 13 November 2025. The Company has presented its case and is now awaiting the Court's decision.

- **Holista Counter-Proceedings (CIV1332 of 2025):** On 31 March 2025, Holista initiated separate proceedings in the Supreme Court of Western Australia against Prolimmune and its director, Dr. Albert Crum. These proceedings involve allegations arising from facts and circumstances related to Prolimmune's action against Holista.
- **Legal Representation:** Holista has appointed new legal counsel to represent the Company in both matters.
- **Outlook:** The outcomes of both proceedings remain uncertain, including the possibility of consolidation. These matters may have material implications for the Company, particularly if summary judgment is granted in CIV1440 of 2025. Holista will provide further updates to the market as developments occur.

Board & Management

No changes to the Board or executive team during the quarter.

Outlook

Holista remains committed to driving sustainable growth in its core Dietary Supplements division; establishing a replacement collagen manufacturing facility in Collie and advancing commercialization of higher-value nano-collagen products; continuing to develop business opportunities other divisions; and maintaining cost efficiency across all operations. With a strengthened liquidity position and positive cash flow momentum, the Company is well-positioned to navigate current challenges and pursue strategic opportunities.

-ENDS-

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

HOLISTA COLLTECH LIMITED (ASX: HCT)

ABN

24 094 515 992

Quarter ended ("current quarter")

31 December 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,700	7,182
1.2	Payments for:		
	(a) research and development	(2)	(30)
	(b) product manufacturing and operating costs	(742)	(3,738)
	(c) advertising and marketing	(274)	(1,188)
	(d) leased assets	-	-
	(e) staff costs	(394)	(1,865)
	(f) administration and corporate costs	(114)	(687)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	4	5
1.5	Interest and other costs of finance paid	(26)	(107)
1.6	Income taxes paid	86	(18)
1.7	Government grants and tax incentives	-	-
1.8	Other (ASIC Penalty)	-	(900)
1.9	Net cash from / (used in) operating activities	238	(1,346)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(15)	(23)
	(d) investments	(123)	(153)
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from the disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) Investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(138)	(176)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	2,295	2,295
3.2	Proceeds from issue of convertible debt securities	-	1,552
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,327	6,196
3.6	Repayment of borrowings	(1,642)	(6,396)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	1,980	3,647
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	52	22
4.2	Net cash from / (used in) operating activities (item 1.9 above)	238	(1,346)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(138)	(176)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,980	3,647
4.5	Effect of movement in exchange rates on cash held	29	14
4.6	Cash and cash equivalents at end of period	2,161	2,161

**Forex adjustment

Quarterly cash flow report for entities subject to Listing Rule 4.7B

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,057	52
5.2	Call deposits	1,104	-
5.3	Bank overdrafts	-	-
5.4	Other (Restricted Cash)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,161	52

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	42
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Fees include Salaries, Director Fees and Consulting Fees to Executive Director and Non-Executive Directors</p>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	445	445
7.2	Credit standby arrangements	2,392	1,110
7.3	Other (please specify)		
7.4	Total financing facilities	2,837	1,555
7.5	Unused financing facilities available at quarter end		1,282
7.6	Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	Summary of Banking Facilities:		
	<u>Bank Loan Facility 1:</u>		
	Parties: CIMB Islamic Bank Berhad Malaysia (Banker), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Collect Ltd) (Borrower).		
	i) Loan Facility 1		
	Term Loan		
	Principal Amount: MYR 1.4M / approximately A\$515k		
	Remaining Payable as at 31 Dec 2025: MYR 1.13M / approximately A\$415k		
	Term: Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of \$3,207 (2024: \$3,186) and ending in 200 months on 4 October 2040.		
	Interest Rate: 3.74% per annum (2024: 3.74%).		
	ii) Credit Standby Arrangement 1		
	Trade Financing and Banker Acceptances bears interest of 5.18% per annum (2024: 5.07%).		
	Total Amount at Quarter End: MYR 2M / Approximately A\$736k		
	Total Utilised at Quarter End: MYR 1.550K / Approximately A\$570k		
	Bank Loan Facility 1 is secured by the following:		
	<ul style="list-style-type: none"> • Fixed deposit with a licensed bank of the Group and the Company; • Facility agreement; • First party assignment over the office lots of the Company; • Deed of assignment of rental proceeds; • Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and • Guarantee by a director of the Company. 		
	Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:		
	<ul style="list-style-type: none"> • "Accepted Bills-i", to facilitate local and export sales of the Borrower; • "Multi Currency Trade Financing-i", to facilitate local and export sales of the Borrower; and • "Bank Guarantee", for issuance of financial, performance and security bonds to government and private entities, in relation to business. 		

Bank Loan Facility 2:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Loan Facility 2**Term Loan**

Principal Amount: MYR 200K / approximately A\$74K.

Amount Remaining as at 31 Dec 2025: MYR 81k / approximately A\$30k

Term: Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of \$1,445 (2024: \$1,413) and ending in 44 months on 4 November 2027.

Interest Rate: 6.60% per annum (2024: 6.60%).

ii) Credit Standby Arrangement 2

Trade Financing and Banker Acceptance bears interest of 5.19% per annum (2024: 5.09%).

Total Amount at Quarter End: MYR 1.5M / Approximately A\$552k

Total Utilised at Quarter End: MYR 1.466K / Approximately A\$540k

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

Bank Loan Facility 3:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Credit Standby Arrangement 3

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

Total Amount at Quarter End: MYR 3.0M / Approximately A\$1,104k

Total Utilised at Quarter End: MYR A\$392k / Approximately A\$144k

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi-Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi-Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	238
8.2 Cash and cash equivalents at quarter end (item 4.6)	2,161
8.3 Unused finance facilities available at quarter end (item 7.5)	1,282
8.4 Total available funding (item 8.2 + item 8.3)	3,681
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Date: : **30 January 2026**

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

- This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.